{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:30:21Z","timestamp":1792661421967,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Vulvar and vaginal atrophy (VVA) is a chronic medical condition experienced by many postmenopausal women. Symptoms include dyspareunia (pain with intercourse), vaginal dryness, and irritation and may affect sexual activities, relationships, and activities of daily life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The aim of this study is to characterize postmenopausal women's experience with and perception of VVA symptoms, interactions with healthcare professionals (HCPs), and available treatment options.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An online survey was conducted in the United States in women from KnowledgePanel\u00ae, a 56,000-member probability-selected Internet panel projectable to the overall US population. Altogether, 3,046 postmenopausal women with VVA symptoms (the largest US cohort of recent surveys) responded to questions about their knowledge of VVA, impact of symptoms on their activities, communication with HCPs, and use of available treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Percent is calculated as the ratio of response over total responding for each question for all and stratified participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common VVA symptoms were dryness (55% of participants), dyspareunia (44%), and irritation (37%). VVA symptoms affected enjoyment of sex in 59% of participants. Additionally, interference with sleep, general enjoyment of life, and temperament were reported by 24%, 23%, and 23% of participants, respectively. Few women attributed symptoms to menopause (24%) or hormonal changes (12%). Of all participants, 56% had ever discussed VVA symptoms with an HCP and 40% currently used VVA-specific topical treatments (vaginal over-the-counter [OTC] products [29%] and vaginal prescription therapies [11%]). Of those who had discussed symptoms with an HCP, 62% used OTC products. Insufficient symptom relief and inconvenience were cited as major limitations of OTC products and concerns about side effects and cancer risk limited use of topical vaginal prescription therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>VVA symptoms are common in postmenopausal women. Significant barriers to treatment include lack of knowledge about VVA, reluctance to discuss symptoms with HCPs, safety concerns, inconvenience, and inadequate symptom relief from available treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jsm.12190","type":"journal-article","created":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T13:39:28Z","timestamp":1368711568000},"page":"1790-1799","source":"Crossref","is-referenced-by-count":404,"title":["Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey"],"prefix":"10.1093","volume":"10","author":[{"given":"Sheryl A.","family":"Kingsberg","sequence":"first","affiliation":[{"name":"Departments of Reproductive Biology and Psychiatry \u00a0 , Cleveland, OH , USA"},{"name":"Case Western University \u00a0 , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wysocki","sequence":"additional","affiliation":[{"name":"iWomensHealth , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Magnus","sequence":"additional","affiliation":[{"name":"Medical Affairs Department \u00a0 , Florham Park, NJ , USA"},{"name":"Shionogi, Inc. \u00a0 , Florham Park, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Krychman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology \u00a0 , Newport Beach, CA , USA"},{"name":"Southern California Center for Sexual Health and Survivorship Medicine \u00a0 , Newport Beach, CA , USA"},{"name":"Obstetrics and Gynecology \u00a0 , Irvine, CA , USA"},{"name":"University of California\u2013Irvine \u00a0 , Irvine, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"key":"2024032601030138800_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"3 Pt 1","key":"2024032601030138800_bb0015","first-page":"355","article-title":"The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society","volume":"14","author":"North American Menopause Society","year":"2007","journal-title":"Menopause"},{"key":"2024032601030138800_bb0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/gme.0b013e3182227ebd","article-title":"Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative","volume":"18","author":"Gass","year":"2011","journal-title":"Menopause"},{"key":"2024032601030138800_bb0025","volume-title":"Age and Sex Composition: 2010","author":"US Census Bureau","year":"2011"},{"key":"2024032601030138800_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal Health: Insights, Views & Attitudes (VIVA)\u2014Results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"2024032601030138800_bb0035","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women","volume":"6","author":"Santoro","year":"2009","journal-title":"J Sex Med"},{"key":"2024032601030138800_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","article-title":"Recommendations for the management of postmenopausal vaginal atrophy","volume":"13","author":"Sturdee","year":"2010","journal-title":"Climacteric"},{"key":"2024032601030138800_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/gme.0b013e31821f92df","article-title":"Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review","volume":"19","author":"Tan","year":"2012","journal-title":"Menopause"},{"key":"2024032601030138800_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jwh.2007.0407","article-title":"A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: Implications for clinical practice","volume":"17","author":"Shulman","year":"2008","journal-title":"J Womens Health (Larchmt)"},{"key":"2024032601030138800_bb0055","volume-title":"REVEAL: REvealing Vaginal Effects At mid-Life. Surveys of Postmenopausal Women and Health Care Professionals Who Treat Postmenopausal Women","author":"Wyeth","year":"2009"},{"key":"2024032601030138800_bb0060","volume-title":"Healthy women survey","author":"Pfizer Pharmaceuticals, Inc"},{"key":"2024032601030138800_bb0065","volume-title":"Data reveal the negative emotional and physical impact that a silent symptom of menopause has on U.S. women and their partners","author":"Novo Nordisk"},{"key":"2024032601030138800_bb0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1743-6109.2011.02543.x","article-title":"To lube or not to lube: Experiences and perceptions of lubricant use in women with and without dyspareunia","volume":"9","author":"Sutton","year":"2012","journal-title":"J Sex Med"},{"key":"2024032601030138800_bb0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/gme.0b013e3181d0f6b9","article-title":"Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","author":"North American Menopause Society","year":"2010","journal-title":"Menopause"},{"key":"2024032601030138800_bb0080","volume-title":"Lake Research Partners","year":"2012"},{"key":"2024032601030138800_bb0085","volume-title":"Vagifem\u00ae (estradiol vaginal tablets) [prescribing information]","year":"2012"},{"key":"2024032601030138800_bb0090","volume-title":"Estrace\u00ae (estradiol vaginal cream) [prescribing information]","year":"2011"},{"key":"2024032601030138800_bb0095","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1743-6109.2010.02114.x","article-title":"Vaginal estrogens for the treatment of dyspareunia","volume":"8","author":"Krychman","year":"2011","journal-title":"J Sex Med"},{"key":"2024032601030138800_bb0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1743-6109.2010.01988.x","article-title":"Simple strategies for vaginal health promotion in cancer survivors","volume":"8","author":"Carter","year":"2011","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515304318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/7\/1790\/48192489\/jsm_10_7_1790.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/7\/1790\/48192489\/jsm_10_7_1790.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:52:03Z","timestamp":1711417923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/10\/7\/1790\/6940054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,1]]},"published-print":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12190","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,7]]},"published":{"date-parts":[[2013,7,1]]}}}